JP2018536649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536649A5 JP2018536649A5 JP2018522026A JP2018522026A JP2018536649A5 JP 2018536649 A5 JP2018536649 A5 JP 2018536649A5 JP 2018522026 A JP2018522026 A JP 2018522026A JP 2018522026 A JP2018522026 A JP 2018522026A JP 2018536649 A5 JP2018536649 A5 JP 2018536649A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- imidazo
- phenyl
- quinolin
- dimethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 26
- -1 3-methoxycyclobut-1-yl Chemical group 0.000 claims description 25
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 9
- 229960005243 carmustine Drugs 0.000 claims description 9
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 229960004679 doxorubicin Drugs 0.000 claims description 8
- 108010006654 Bleomycin Proteins 0.000 claims description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 7
- 229960001561 bleomycin Drugs 0.000 claims description 7
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 7
- 229960004630 chlorambucil Drugs 0.000 claims description 7
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 7
- 229960004397 cyclophosphamide Drugs 0.000 claims description 7
- 229960005420 etoposide Drugs 0.000 claims description 7
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 7
- 229960001101 ifosfamide Drugs 0.000 claims description 7
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 7
- 229960004768 irinotecan Drugs 0.000 claims description 7
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 7
- 229960004857 mitomycin Drugs 0.000 claims description 7
- 229960000303 topotecan Drugs 0.000 claims description 7
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 7
- BKWJAKQVGHWELA-UHFFFAOYSA-N 1-[6-(2-hydroxypropan-2-yl)-2-pyridinyl]-6-[4-(4-methyl-1-piperazinyl)anilino]-2-prop-2-enyl-3-pyrazolo[3,4-d]pyrimidinone Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N(CC=C)N(C=3N=C(C=CC=3)C(C)(C)O)C2=N1 BKWJAKQVGHWELA-UHFFFAOYSA-N 0.000 claims description 6
- 229930192392 Mitomycin Natural products 0.000 claims description 6
- 229950009557 adavosertib Drugs 0.000 claims description 6
- 229960002707 bendamustine Drugs 0.000 claims description 6
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 6
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 5
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 5
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims description 5
- 229960002550 amrubicin Drugs 0.000 claims description 5
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims description 5
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 5
- 229960004562 carboplatin Drugs 0.000 claims description 5
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- 229960001904 epirubicin Drugs 0.000 claims description 5
- 229960001924 melphalan Drugs 0.000 claims description 5
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 229960000572 olaparib Drugs 0.000 claims description 5
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 5
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 5
- 229960001756 oxaliplatin Drugs 0.000 claims description 5
- 229960001221 pirarubicin Drugs 0.000 claims description 5
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 4
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229950009791 durvalumab Drugs 0.000 claims description 4
- 229960000908 idarubicin Drugs 0.000 claims description 4
- 229960000653 valrubicin Drugs 0.000 claims description 4
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 5
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- NSHFLKZNBPJNPA-UHFFFAOYSA-N imidazo[4,5-c]quinolin-2-one Chemical compound C1=CC=C2C3=NC(=O)N=C3C=NC2=C1 NSHFLKZNBPJNPA-UHFFFAOYSA-N 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- PBQDFTZTPPULAN-AZGAKELHSA-N 1-[(1S,3R)-3-methoxycyclohexyl]-3-methyl-8-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]imidazo[4,5-c]quinolin-2-one Chemical compound CO[C@@H]1CCC[C@@H](C1)n1c2c(cnc3ccc(cc23)-c2ccc(OCCCN3CCCC3)cc2)n(C)c1=O PBQDFTZTPPULAN-AZGAKELHSA-N 0.000 claims 2
- BWFJHLCIUJECFJ-LADGPHEKSA-N 8-[4-[3-(dimethylamino)propoxy]phenyl]-1-[(1S,3R)-3-methoxycyclohexyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1C[C@@H](CCC1)OC)=O)C)C BWFJHLCIUJECFJ-LADGPHEKSA-N 0.000 claims 2
- BWFJHLCIUJECFJ-UPVQGACJSA-N 8-[4-[3-(dimethylamino)propoxy]phenyl]-1-[(1S,3S)-3-methoxycyclohexyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1C[C@H](CCC1)OC)=O)C)C BWFJHLCIUJECFJ-UPVQGACJSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- DVOMFJSXXSMBLR-ZRZAMGCNSA-N CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1CC[C@@H](CC1)OC)=O)C)C Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1CC[C@@H](CC1)OC)=O)C)C DVOMFJSXXSMBLR-ZRZAMGCNSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- QWLLFXDZPBLPOP-AHWVRZQESA-N 1-[(1S,3S)-3-methoxycyclopentyl]-3-methyl-8-[4-(3-piperidin-1-ylpropoxy)phenyl]imidazo[4,5-c]quinolin-2-one Chemical compound CO[C@H]1CC[C@@H](C1)N1C(=O)N(C)C2=C1C1=CC(=CC=C1N=C2)C1=CC=C(OCCCN2CCCCC2)C=C1 QWLLFXDZPBLPOP-AHWVRZQESA-N 0.000 claims 1
- VPQISSQURVSVEH-UHFFFAOYSA-N 1-cyclobutyl-8-[4-[2-(dimethylamino)ethoxy]phenyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound C1(CCC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C1=CC=C(C=C1)OCCN(C)C)C)=O VPQISSQURVSVEH-UHFFFAOYSA-N 0.000 claims 1
- HNGQMAWSKLQFDG-UHFFFAOYSA-N 3-methyl-1-(oxan-4-yl)-8-[4-(3-piperidin-1-ylpropoxy)phenyl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C1=CC=C(C=C1)OCCCN1CCCCC1)C1CCOCC1)=O HNGQMAWSKLQFDG-UHFFFAOYSA-N 0.000 claims 1
- FASVMHFSMHRYNN-HSZRJFAPSA-N 3-methyl-1-[(3R)-oxan-3-yl]-8-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C1=CC=C(C=C1)OCCCN1CCCC1)[C@H]1COCCC1)=O FASVMHFSMHRYNN-HSZRJFAPSA-N 0.000 claims 1
- FASVMHFSMHRYNN-QHCPKHFHSA-N 3-methyl-1-[(3S)-oxan-3-yl]-8-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C1=CC=C(C=C1)OCCCN1CCCC1)[C@@H]1COCCC1)=O FASVMHFSMHRYNN-QHCPKHFHSA-N 0.000 claims 1
- IGOJVOACVMDYGE-QHCPKHFHSA-N 3-methyl-1-[(3S)-oxolan-3-yl]-8-[4-(3-piperidin-1-ylpropoxy)phenyl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C1=CC=C(C=C1)OCCCN1CCCCC1)[C@@H]1COCC1)=O IGOJVOACVMDYGE-QHCPKHFHSA-N 0.000 claims 1
- NMIHWXNHIAKYMO-UHFFFAOYSA-N 3-methyl-1-propan-2-yl-8-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]imidazo[4,5-c]quinolin-2-one Chemical compound C(C)(C)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C1=CC=C(C=C1)OCCCN1CCCC1)C)=O NMIHWXNHIAKYMO-UHFFFAOYSA-N 0.000 claims 1
- XCJZNPINCKRQJY-UHFFFAOYSA-N 7-fluoro-3-methyl-1-(oxan-4-yl)-8-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]imidazo[4,5-c]quinolin-2-one Chemical compound FC=1C(=CC=2C3=C(C=NC=2C=1)N(C(N3C1CCOCC1)=O)C)C1=CC=C(C=C1)OCCCN1CCCC1 XCJZNPINCKRQJY-UHFFFAOYSA-N 0.000 claims 1
- HLLZYCKUFIESHR-UNMCSNQZSA-N 8-[4-[2-(dimethylamino)ethoxy]phenyl]-1-[(1S,3S)-3-methoxycyclopentyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound CN(CCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1C[C@H](CC1)OC)=O)C)C HLLZYCKUFIESHR-UNMCSNQZSA-N 0.000 claims 1
- CQJAMPNLRXCFSQ-UHFFFAOYSA-N 8-[4-[2-(dimethylamino)ethoxy]phenyl]-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN(CCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3C1CCOCC1)=O)C)C CQJAMPNLRXCFSQ-UHFFFAOYSA-N 0.000 claims 1
- GLIDQHAUAKRTCP-HXUWFJFHSA-N 8-[4-[2-(dimethylamino)ethoxy]phenyl]-3-methyl-1-[(3R)-oxan-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN(CCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@H]1COCCC1)=O)C)C GLIDQHAUAKRTCP-HXUWFJFHSA-N 0.000 claims 1
- GLIDQHAUAKRTCP-FQEVSTJZSA-N 8-[4-[2-(dimethylamino)ethoxy]phenyl]-3-methyl-1-[(3S)-oxan-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN(CCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1COCCC1)=O)C)C GLIDQHAUAKRTCP-FQEVSTJZSA-N 0.000 claims 1
- MVPGVNABVQXLLG-UHFFFAOYSA-N 8-[4-[2-(dimethylamino)ethoxy]phenyl]-3-methyl-1-propan-2-ylimidazo[4,5-c]quinolin-2-one Chemical compound CN(CCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3C(C)C)=O)C)C MVPGVNABVQXLLG-UHFFFAOYSA-N 0.000 claims 1
- HXZGHFRHTWCGIR-UHFFFAOYSA-N 8-[4-[3-(azetidin-1-yl)propoxy]phenyl]-3-methyl-1-propan-2-ylimidazo[4,5-c]quinolin-2-one Chemical compound N1(CCC1)CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3C(C)C)=O)C HXZGHFRHTWCGIR-UHFFFAOYSA-N 0.000 claims 1
- YYQJJTPKNSHODU-UNMCSNQZSA-N 8-[4-[3-(azetidin-1-yl)propoxy]phenyl]-7-fluoro-1-[(1S,3S)-3-methoxycyclopentyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound N1(CCC1)CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1F)N(C(N3[C@@H]1C[C@H](CC1)OC)=O)C YYQJJTPKNSHODU-UNMCSNQZSA-N 0.000 claims 1
- TYXGSHZVXIYHKG-UHFFFAOYSA-N 8-[4-[3-(azetidin-1-yl)propoxy]phenyl]-7-fluoro-3-methyl-1-propan-2-ylimidazo[4,5-c]quinolin-2-one Chemical compound N1(CCC1)CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1F)N(C(N3C(C)C)=O)C TYXGSHZVXIYHKG-UHFFFAOYSA-N 0.000 claims 1
- VICUFCKPAORKNQ-FYYLOGMGSA-N 8-[4-[3-(dimethylamino)propoxy]phenyl]-1-[(1R,3R)-3-methoxycyclopentyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@H]1C[C@@H](CC1)OC)=O)C)C VICUFCKPAORKNQ-FYYLOGMGSA-N 0.000 claims 1
- VICUFCKPAORKNQ-GMAHTHKFSA-N 8-[4-[3-(dimethylamino)propoxy]phenyl]-1-[(1S,3S)-3-methoxycyclopentyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1C[C@H](CC1)OC)=O)C)C VICUFCKPAORKNQ-GMAHTHKFSA-N 0.000 claims 1
- KLLHVKGDRGFZKW-UHFFFAOYSA-N 8-[4-[3-(dimethylamino)propoxy]phenyl]-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3C1CCOCC1)=O)C)C KLLHVKGDRGFZKW-UHFFFAOYSA-N 0.000 claims 1
- XMTRDVDPMSLYSE-OAQYLSRUSA-N 8-[4-[3-(dimethylamino)propoxy]phenyl]-3-methyl-1-[(3R)-oxan-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@H]1COCCC1)=O)C)C XMTRDVDPMSLYSE-OAQYLSRUSA-N 0.000 claims 1
- XMTRDVDPMSLYSE-NRFANRHFSA-N 8-[4-[3-(dimethylamino)propoxy]phenyl]-3-methyl-1-[(3S)-oxan-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1COCCC1)=O)C)C XMTRDVDPMSLYSE-NRFANRHFSA-N 0.000 claims 1
- WHPSNGOGYDRWMF-UHFFFAOYSA-N 8-[4-[3-(dimethylamino)propoxy]phenyl]-3-methyl-1-propan-2-ylimidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3C(C)C)=O)C)C WHPSNGOGYDRWMF-UHFFFAOYSA-N 0.000 claims 1
- CTSQGUOQTINESS-PZJWPPBQSA-N 8-[4-[3-(dimethylamino)propoxy]phenyl]-7-fluoro-1-[(1S,3R)-3-methoxycyclopentyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound CO[C@@H]1CC[C@@H](C1)n1c2c(cnc3cc(F)c(cc23)-c2ccc(OCCCN(C)C)cc2)n(C)c1=O CTSQGUOQTINESS-PZJWPPBQSA-N 0.000 claims 1
- CTSQGUOQTINESS-FPOVZHCZSA-N 8-[4-[3-(dimethylamino)propoxy]phenyl]-7-fluoro-1-[(1S,3S)-3-methoxycyclopentyl]-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1F)N(C(N3[C@@H]1C[C@H](CC1)OC)=O)C)C CTSQGUOQTINESS-FPOVZHCZSA-N 0.000 claims 1
- WSZRRVZXMQMSMO-UHFFFAOYSA-N 8-[4-[3-(dimethylamino)propoxy]phenyl]-7-fluoro-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1F)N(C(N3C1CCOCC1)=O)C)C WSZRRVZXMQMSMO-UHFFFAOYSA-N 0.000 claims 1
- HRCFWXQOXVPPRO-IBGZPJMESA-N 8-[4-[3-(dimethylamino)propoxy]phenyl]-7-fluoro-3-methyl-1-[(3S)-oxan-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1F)N(C(N3[C@@H]1COCCC1)=O)C)C HRCFWXQOXVPPRO-IBGZPJMESA-N 0.000 claims 1
- UZMFQVNEIZJHHD-GRGXKFILSA-N CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1C[C@@H](C1)OC)=O)C)C Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1C[C@@H](C1)OC)=O)C)C UZMFQVNEIZJHHD-GRGXKFILSA-N 0.000 claims 1
- UZMFQVNEIZJHHD-AQYVVDRMSA-N CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1C[C@H](C1)OC)=O)C)C Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1C[C@H](C1)OC)=O)C)C UZMFQVNEIZJHHD-AQYVVDRMSA-N 0.000 claims 1
- KHSKHNZDPPJCIX-PUZFROQSSA-N CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1F)N(C(N3[C@@H]1C[C@@H](C1)OC)=O)C)C Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1F)N(C(N3[C@@H]1C[C@@H](C1)OC)=O)C)C KHSKHNZDPPJCIX-PUZFROQSSA-N 0.000 claims 1
- WQVGADKFYLASLP-TYKWCNGQSA-N CN(CCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1C[C@@H](C1)OC)=O)C)C Chemical compound CN(CCOC1=CC=C(C=C1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1C[C@@H](C1)OC)=O)C)C WQVGADKFYLASLP-TYKWCNGQSA-N 0.000 claims 1
- ZTVFABHBBXHMKM-QUPDYRNUSA-N CO[C@H]1C[C@H](C1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C1=CC=C(C=C1)OCCCN1CCCC1)C)=O Chemical compound CO[C@H]1C[C@H](C1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C1=CC=C(C=C1)OCCCN1CCCC1)C)=O ZTVFABHBBXHMKM-QUPDYRNUSA-N 0.000 claims 1
- AWHGTSZPURVFEA-GUOBSTCESA-N CO[C@H]1C[C@H](C1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C1=CC=C(C=C1)OCCCN1CCCCC1)C)=O Chemical compound CO[C@H]1C[C@H](C1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C1=CC=C(C=C1)OCCCN1CCCCC1)C)=O AWHGTSZPURVFEA-GUOBSTCESA-N 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 238000013459 approach Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 1
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 101150062285 PGF gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 102100023037 Wee1-like protein kinase Human genes 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1519406.1A GB201519406D0 (en) | 2015-11-03 | 2015-11-03 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| GB1519406.1 | 2015-11-03 | ||
| PCT/EP2016/076412 WO2017076895A1 (en) | 2015-11-03 | 2016-11-02 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018536649A JP2018536649A (ja) | 2018-12-13 |
| JP2018536649A5 true JP2018536649A5 (enExample) | 2019-12-12 |
Family
ID=55130605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522026A Withdrawn JP2018536649A (ja) | 2015-11-03 | 2016-11-02 | イミダゾ［４，５−ｃ］キノリン−２−オン化合物及び癌の治療におけるその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20180318287A1 (enExample) |
| EP (1) | EP3371183A1 (enExample) |
| JP (1) | JP2018536649A (enExample) |
| KR (1) | KR20180070703A (enExample) |
| CN (1) | CN108349971A (enExample) |
| AU (1) | AU2016348546B2 (enExample) |
| BR (1) | BR112018007772A2 (enExample) |
| CA (1) | CA3002608A1 (enExample) |
| CL (1) | CL2018001146A1 (enExample) |
| CO (1) | CO2018003969A2 (enExample) |
| CR (1) | CR20180307A (enExample) |
| GB (1) | GB201519406D0 (enExample) |
| HK (2) | HK1255598A1 (enExample) |
| IL (1) | IL258818A (enExample) |
| MX (1) | MX2018005445A (enExample) |
| PE (1) | PE20181345A1 (enExample) |
| PH (1) | PH12018500958A1 (enExample) |
| RU (1) | RU2018120318A (enExample) |
| SV (1) | SV2018005663A (enExample) |
| WO (1) | WO2017076895A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| WO2019057757A1 (en) | 2017-09-20 | 2019-03-28 | Astrazeneca Ab | 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER |
| CN110386932A (zh) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| CN115636833B (zh) | 2018-09-14 | 2024-11-29 | 苏州赞荣医药科技有限公司 | 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途 |
| BR112021005989A2 (pt) * | 2018-09-30 | 2021-06-29 | Medshine Discovery Inc. | derivados de quinolino-pirrolidin-2-ona e aplicação dos mesmos |
| EP3935060B1 (en) * | 2019-03-05 | 2023-11-15 | Astrazeneca AB | Fused tricyclic compounds useful as anticancer agents |
| CN114746421A (zh) * | 2019-11-19 | 2022-07-12 | 南京明德新药研发有限公司 | 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用 |
| WO2021139814A1 (zh) * | 2020-01-09 | 2021-07-15 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
| WO2021197339A1 (zh) * | 2020-03-30 | 2021-10-07 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
| JP2023539715A (ja) | 2020-06-24 | 2023-09-19 | アストラゼネカ ユーケー リミテッド | 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ |
| AU2020468487B2 (en) * | 2020-09-21 | 2024-02-29 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo(4,5-c) quinolin-2-one compounds with blood-brain barrier penetrable capability |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| WO2022128833A1 (en) | 2020-12-15 | 2022-06-23 | Merck Patent Gmbh | Solid transition metal-ligand complexes |
| CN120247909A (zh) * | 2022-01-26 | 2025-07-04 | 正大天晴药业集团股份有限公司 | 含有肼基的化合物 |
| EP4469050A4 (en) * | 2022-04-11 | 2025-04-02 | Wei Zhong | CRYSTALLINE FORM OF SUBSTITUTED 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVE, CRYSTALLINE SALT FORM, PREPARATION METHOD AND APPLICATION |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100311714A1 (en) * | 2009-06-04 | 2010-12-09 | Pascal Furet | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS |
| CN102372711B (zh) * | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| CN102399218A (zh) * | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| NO2714752T3 (enExample) * | 2014-05-08 | 2018-04-21 | ||
| CA2981365A1 (en) * | 2015-04-02 | 2016-10-06 | Merck Patent Gmbh | Imidazolonylquinolines and the use thereof as atm kinase inhibitors |
-
2015
- 2015-11-03 GB GBGB1519406.1A patent/GB201519406D0/en not_active Ceased
-
2016
- 2016-11-02 WO PCT/EP2016/076412 patent/WO2017076895A1/en not_active Ceased
- 2016-11-02 RU RU2018120318A patent/RU2018120318A/ru not_active Application Discontinuation
- 2016-11-02 KR KR1020187015448A patent/KR20180070703A/ko not_active Withdrawn
- 2016-11-02 MX MX2018005445A patent/MX2018005445A/es unknown
- 2016-11-02 AU AU2016348546A patent/AU2016348546B2/en not_active Ceased
- 2016-11-02 CN CN201680063688.5A patent/CN108349971A/zh active Pending
- 2016-11-02 BR BR112018007772A patent/BR112018007772A2/pt not_active Application Discontinuation
- 2016-11-02 US US15/772,118 patent/US20180318287A1/en not_active Abandoned
- 2016-11-02 HK HK18114727.1A patent/HK1255598A1/zh unknown
- 2016-11-02 CA CA3002608A patent/CA3002608A1/en not_active Abandoned
- 2016-11-02 EP EP16790601.5A patent/EP3371183A1/en not_active Withdrawn
- 2016-11-02 JP JP2018522026A patent/JP2018536649A/ja not_active Withdrawn
- 2016-11-02 HK HK19100042.7A patent/HK1257678A1/zh unknown
- 2016-11-02 PE PE2018000612A patent/PE20181345A1/es unknown
- 2016-11-02 CR CR20180307A patent/CR20180307A/es unknown
-
2018
- 2018-04-06 SV SV2018005663A patent/SV2018005663A/es unknown
- 2018-04-13 CO CONC2018/0003969A patent/CO2018003969A2/es unknown
- 2018-04-22 IL IL258818A patent/IL258818A/en unknown
- 2018-04-30 CL CL2018001146A patent/CL2018001146A1/es unknown
- 2018-05-03 PH PH12018500958A patent/PH12018500958A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018536649A5 (enExample) | ||
| JP2019501873A5 (enExample) | ||
| Zhang et al. | Targeted chemo-photodynamic combination platform based on the DOX prodrug nanoparticles for enhanced cancer therapy | |
| ES2992591T3 (en) | Compositions, combinations and related methods for photoimmunotherapy | |
| ES2802296T3 (es) | Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK | |
| JP2023519247A (ja) | Ｆａｐ標的化放射性医薬品およびイメージング剤、ならびにそれらに関連する使用 | |
| CN108712904B (zh) | 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途 | |
| JP2023526501A (ja) | 金属有機構造体が癌免疫療法の為の低分子及びバイオ高分子を送達する | |
| RU2016124731A (ru) | Рецептор-направленные конструкции и их применение | |
| CN112512583B (zh) | 酞菁染料偶联物组合物 | |
| US20220211883A1 (en) | Fap-activated radiotheranostics and uses related thereto | |
| CN113811298B (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| CN109069531A (zh) | 铂抗癌剂 | |
| US20210361563A1 (en) | Transdermal system for synergistic immune-chemotherapy using microneedles and method of treatment thereof | |
| WO2011022350A1 (en) | Zinc nanoparticles for the treatment of infections and cancer | |
| US11191745B2 (en) | Silica nanoparticle with an insoluble drug | |
| JP7636322B2 (ja) | 癌を処置するためのマドラシン誘導体化合物、組成物およびこれらの使用 | |
| EP2926815A1 (en) | New derivatives of cephalosporin for treating cancer | |
| ES2859679T3 (es) | Compuestos, composición y usos de los mismos para tratar el cáncer | |
| Zhang et al. | NK-derived exosomes in anti-tumor strategies | |
| Verschuere et al. | Enhancing anti-tumor immunity through intratumoral combination therapy with amphiphilic conjugates of oxaliplatin and imidazoquinoline TLR7/8 agonist | |
| Djermane | Study of the Physicochemical Properties of Polydopamine Nanoparticles and Their Application in the Development of Tailored Drug Delivery Nanocarriers for Cancer Theraphy | |
| Sang | Hafnium-Based Metal-Phenolic Networks for Combinational Cancer Radio-Immunotherapy | |
| Pacheco et al. | Rational design of anticancer multidrug nanosystems and their adaptation for glioblastoma treatment | |
| Conte | Multimodal Therapies for Pancreatic Ductal Adenocarcinoma: Ultrasound-Stimulated Nanoconstructs based on Lipid-coated Zinc Oxide |